KRYS

Krystal Biotech Inc

305.03

Nov 03 • 3:59 PM ET +9.13 (3.09%)

315.00

Aftermarket • 6:12 PM ET +9.97 (3.27%)

Healthcare Biotechnology USA Mid NASD

Nov 02, 5:08 PMKrystal Biotech posts Q3 2026 beat as VYJUVEK drives 30% revenue growth, cuts 2026 opex guidance and authorizes $400m buyback

Peers: ABEO BMRN SRPT PTCT RARE VCEL RGNX RYTM ARQT RCKT

| Held by: IJH VTI VB IWM XBI VBK VXF XMMO IWO DFAS

Scroll to Statements

Index	RUT
Market Cap	9.03B
Enterprise Value	8.13B
Income	225.17M
Sales	470.02M
Book/sh	48.45
Cash/sh	30.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	295
IPO	Sep 20, 2017

P/E	41.42
Forward P/E	32.92
PEG	1.68
P/S	19.21
P/B	6.30
P/C	9.90
P/FCF	29.12
EV/EBITDA	34.68
EV/Sales	17.29
Quick Ratio	7.53
Current Ratio	7.89
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	7.36
EPS next Y	9.27
EPS next Q	2.05
EPS this Y	12.32%
EPS next Y	20.62%
EPS next 5Y	19.63%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	11.21%
Sales Y/Y TTM	25.96%
EPS Q/Q	-23.13%
Sales Q/Q	30.21%
Earnings	Nov 02 BMO
EPS/Sales Surpr.	14.59% 1.25%

Insider Own	12.26%
Insider Trans	-3.37%
Inst Own	98.69%
Inst Trans	0.24%
ROA	15.93%
ROE	17.50%
ROIC	15.61%
Gross Margin	93.02%
Oper. Margin	48.41%
Profit Margin	47.91%
SMA20	-5.08%
SMA50	-9.14%
SMA200	-1.19%
Trades

Shs Outstand	29.63M
Shs Float	25.97M
Short Float	11.31%
Short Ratio	10.25
Short Interest	2.94M
52W High	382.54 -20.26%
52W Low	184.02 65.76%
Volatility	4.80% 3.70%
ATR (14)	12.94
RSI (14)	40.48
Beta	0.66
Rel Volume	2.11
Avg Volume	286.58K
Volume	603,291

Perf Week	-4.85%
Perf Month	-8.91%
Perf Quarter	-6.37%
Perf Half Y	7.19%
Perf YTD	23.72%
Perf Year	54.17%
Perf 3Y	149.72%
Perf 5Y	478.15%
Perf 10Y	-
Recom	1.25
Target Price	401.25
Prev Close	295.90
Price	305.03
Change %	3.09%

Consensus

Strong Buy

Avg. Price Target

$401.25

Implied Upside

+31.5%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 24, 2026	Resumed	GGoldman	Buy	$441	+44.6%
Aug 14, 2026	Initiated	RRBC Capital Mkts	Outperform	$400	+31.1%
Mar 27, 2026	Initiated	WWolfe Research	Peer Perform
Jan 06, 2026	Upgrade	CCitigroup	Neutral → Buy	$309	+1.3%
Mar 05, 2025	Initiated	JJefferies	Buy	$245	-19.7%
Aug 06, 2024	Downgrade	CCitigroup	Buy → Neutral	$195 → $204	-33.1%
Nov 20, 2023	Initiated	GGoldman	Buy	$160	-47.5%
Oct 24, 2023	Initiated	CCantor Fitzgerald	Overweight	$100	-67.2%
Oct 12, 2023	Initiated	CCitigroup	Buy	$160	-47.5%
Sep 07, 2023	Initiated	BBerenberg	Buy	$154	-49.5%
Apr 18, 2023	Initiated	SStifel	Buy	$102	-66.6%
Feb 28, 2023	Upgrade	GGoldman	Neutral → Buy	$79 → $124	-59.3%
Aug 25, 2022	Downgrade	GGoldman	Buy → Neutral	$74	-75.7%
Jan 18, 2022	Initiated	BBofA Securities	Buy	$110	-63.9%
Jul 20, 2021	Upgrade	GGoldman	Neutral → Buy	$73 → $90	-70.5%
Sep 18, 2020	Initiated	BB. Riley FBR	Buy	$100	-67.2%
Jun 04, 2020	Initiated	EEvercore ISI	Outperform	$90	-70.5%
Sep 24, 2019	Initiated	GGoldman	Neutral	$60	-80.3%
Aug 06, 2019	Reiterated	HH.C. Wainwright	Buy	$56 → $59	-80.7%
Jun 24, 2019	Reiterated	HH.C. Wainwright	Buy	$38 → $56	-81.6%

Nov-02-26 11:03AM	Krystal Biotech Beats On Vyjuvek Strength And Adds A $400 Million Buyback, But Pipeline Timelines Slip Into 2027 (Earnings Whispers) -10.95%
08:42AM	Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth (InvestorsHub)
07:00AM	Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
Oct-26-26 11:45AM	Krystal Biotech's Germany Pricing Drag Tests Whether Vyjuvek Demand Can Carry Q3 (Earnings Whispers)
Oct-22-26 08:00AM	Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 (GlobeNewswire)
10:06AM	Loading…
Oct-15-26 10:06AM	Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin (InvestorsHub)
07:00AM	Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome (GlobeNewswire)
Oct-06-26 12:30PM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (FinanceWire)
Sep-03-26 08:00AM	Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-26 11:33AM	Earnings Calendar and Analysis for This Week (August 10-14) (Kiplinger)
Aug-04-26 06:20AM	J&J pharma leader to retire; Krystal slumps on gene therapy miss (BioPharma Dive)
Aug-03-26 05:00PM	Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ... (GuruFocus.com) -8.37%
12:45PM	Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test (Investor's Business Daily)
09:38AM	Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble (Investor's Business Daily)
08:29AM	Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts (InvestorsHub)
07:00AM	Loading…
07:00AM	Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
Jul-23-26 05:00PM	Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 (GlobeNewswire)
Jul-20-26 05:42PM	Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 (PR Newswire)
Jun-13-26 08:07AM	Viking, Bloom Energy Lead Five Stocks Making Bullish Moves As Market Rebounds (Investor's Business Daily)
Jun-12-26 08:11AM	Dow Jones Futures Rise, Oil Skids On Iran Deal Hopes; SpaceX IPO Indicated Higher (Investor's Business Daily)
May-18-26 08:00AM	Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa (GlobeNewswire)
May-11-26 02:21PM	This Profitable Biotech Stealthily Climbs Into A Buy Zone (Investor's Business Daily)
May-07-26 08:00AM	Krystal Biotech to Present at BofA Securities 2026 Health Care Conference (GlobeNewswire)
May-04-26 07:00AM	Krystal Biotech Announces First Quarter 2026 Financial and Operating Results (GlobeNewswire) +7.86%
Apr-30-26 08:00AM	Krystal Biotech to Present at Upcoming Scientific Conferences (GlobeNewswire)
Apr-21-26 08:00AM	Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026 (GlobeNewswire)
Feb-28-26 02:21AM	Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 (Insider Monkey)
Feb-24-26 08:00AM	Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-21-26 06:32AM	Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating (Insider Monkey)
Feb-18-26 11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
04:44AM	Loading…
04:44AM	Stock Market News for Feb 18, 2026 (Zacks)
Feb-17-26 04:01PM	Krystal Biotech Inc (KRYS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
10:42AM	Krystal Biotech Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-13-26 05:15PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-10-26 02:41PM	Biotech Stock Nears Entry After FDA News; Earnings On Horizon (Investor's Business Daily)
08:00AM	Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 (GlobeNewswire)
Feb-09-26 08:00AM	Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Feb-03-26 08:58PM	Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision (Insider Monkey)
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
Jan-28-26 08:48AM	5 Stocks With Recent Price to Strengthen Your Portfolio (Zacks)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
Jan-26-26 08:55AM	Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-23-26 12:00PM	Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice (Zacks)
Jan-22-26 02:31PM	Biotech stocks are among today's winners (MarketWatch)
02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks)
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
04:19AM	What Does Wall Street Think About Krystal Biotech (KRYS)? (Insider Monkey)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
08:39AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily) +7.28%
01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks)
Jan-11-26 01:00PM	Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:55AM	Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why (Zacks) +5.02%
Jan-08-26 10:02PM	Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path (MarketBeat)
04:01PM	Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis (GlobeNewswire)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
Jan-07-26 04:05PM	Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis (GlobeNewswire)
Jan-05-26 08:00AM	Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks) +5.48%
Dec-01-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-26-25 08:00AM	Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-18-25 04:45AM	Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT (Insider Monkey)
Nov-14-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-11-25 01:04PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-03-25 04:01PM	Krystal Biotech Inc (KRYS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Global ... (GuruFocus.com)
07:00AM	Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Oct-31-25 09:18AM	Krystal Biotech Inc (KRYS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 10:00AM	Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 08:00AM	Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-17-25 09:27AM	Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-15-25 01:39PM	FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin (Benzinga) +8.37%
08:00AM	Krystal Biotech Announces FDA Approval of Updated VYJUVEK Label (GlobeNewswire)
Sep-12-25 08:39AM	TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS) (Insider Monkey)
Sep-03-25 11:30AM	Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 08:00AM	Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-21-25 12:11PM	Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-05-25 12:00PM	Krystal Biotech price target lowered to $182 from $192 at BofA (TipRanks)
08:59AM	KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook (Zacks)
03:02AM	Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krishnan Suma	President, R&D	Sep 04 '26	Sale	359.32	25,000	8,982,986	1,302,145	Sep 04 07:15 PM
Krishnan Krish S	President and CEO	Sep 04 '26	Sale	359.32	25,000	8,983,084	1,347,543	Sep 04 07:14 PM
SUMA KRISHNAN	Director	Sep 04 '26	Proposed Sale	371.47	25,000	9,286,750		Sep 04 04:34 PM
KRISH KRISHNAN	Director	Sep 04 '26	Proposed Sale	371.47	25,000	9,286,750		Sep 04 04:34 PM
ROSSI DINO A	Director	Aug 14 '26	Sale	329.12	25,000	8,227,953	50,000	Aug 14 06:22 PM
Dino A. Rossi	Director	Aug 14 '26	Proposed Sale	332.27	25,000	8,306,750		Aug 14 05:21 PM
Thomas John Charles	EVP, General Counsel	Jun 25 '26	Option Exercise	179.25	1,000	179,250	1,000	Jun 26 06:45 PM
Thomas John Charles	EVP, General Counsel	Jun 25 '26	Sale	347.27	1,000	347,270	0	Jun 26 06:45 PM
Thomas John Charles	Officer	Jun 25 '26	Proposed Sale	347.27	1,000	347,270		Jun 25 10:03 AM
Krishnan Suma	President, R&D	Jun 04 '26	Sale	308.11	25,000	7,702,825	1,378,155	Jun 05 06:40 PM
Krishnan Krish S	President and CEO	Jun 04 '26	Sale	308.12	25,000	7,702,984	1,450,253	Jun 05 06:38 PM
SUMA KRISHNAN	Director	Jun 04 '26	Proposed Sale	301.82	25,000	7,545,500		Jun 04 04:30 PM
KRISH KRISHNAN	Director	Jun 04 '26	Proposed Sale	301.82	25,000	7,545,500		Jun 04 04:30 PM
Thomas John Charles	EVP, General Counsel	May 26 '26	Sale	302.03	642	193,903	0	May 27 05:17 PM
Thomas John Charles	Officer	May 26 '26	Proposed Sale	302.03	642	193,903		May 26 10:30 AM
Krishnan Suma	President, R&D	Mar 04 '26	Sale	263.21	25,000	6,580,270	1,403,155	Mar 06 06:23 PM
Krishnan Krish S	President and CEO	Mar 04 '26	Sale	263.17	25,000	6,579,164	1,475,253	Mar 06 06:22 PM
SUMA KRISHNAN	Director	Mar 04 '26	Proposed Sale	263.80	25,000	6,595,000		Mar 04 04:40 PM
KRISH KRISHNAN	Director	Mar 04 '26	Proposed Sale	263.80	25,000	6,595,000		Mar 04 04:39 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 27 '26	Option Exercise	0.00	8,050	0	26,068	Mar 03 06:33 PM
ROMANO KATHRYN	Chief Accounting Officer	Mar 02 '26	Sale	267.60	750	200,700	22,366	Mar 03 06:33 PM
Krishnan Suma	President, R&D	Feb 27 '26	Option Exercise	0.00	40,725	0	1,509,075	Mar 03 06:33 PM
Krishnan Suma	President, R&D	Feb 27 '26	Option Exercise	0.00	26,500	0	1,436,211	Mar 03 06:33 PM
Krishnan Krish S	President and CEO	Feb 27 '26	Option Exercise	0.00	26,500	0	1,436,211	Mar 03 06:30 PM
Krishnan Krish S	President and CEO	Feb 27 '26	Option Exercise	0.00	40,725	0	1,509,075	Mar 03 06:30 PM
JANNEY DANIEL	Director	Feb 27 '26	Sale	275.59	11,803	3,252,824	73,293	Mar 03 06:28 PM
ROMANO KATHRYN	Officer	Mar 02 '26	Proposed Sale	267.60	750	200,700		Mar 02 12:56 PM
Daniel S Janney	Director	Feb 27 '26	Proposed Sale	275.59	11,803	3,252,824		Feb 27 04:41 PM
JANNEY DANIEL	Director	Feb 24 '26	Option Exercise	2.46	37,895	93,222	37,895	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 24 '26	Sale	266.88	37,895	10,113,354	0	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 24 '26	Sale	268.34	13,825	3,709,850	93,537	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 26 '26	Sale	275.63	7,741	2,133,679	85,096	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 25 '26	Sale	275.00	700	192,500	92,837	Feb 26 06:49 PM
Daniel S Janney	Director	Feb 26 '26	Proposed Sale	275.63	7,741	2,133,680		Feb 26 04:41 PM
Daniel S Janney	Director	Feb 25 '26	Proposed Sale	275.00	700	192,500		Feb 25 04:38 PM
JANNEY DANIEL	Director	Feb 24 '26	Proposed Sale	266.88	37,895	10,113,354		Feb 24 05:20 PM
Daniel S Janney	Director	Feb 24 '26	Proposed Sale	268.34	13,825	3,709,850		Feb 24 04:39 PM
ROSSI DINO A	Director	Feb 19 '26	Option Exercise	8.79	18,950	166,570	97,641	Feb 23 07:14 PM
ROSSI DINO A	Director	Feb 19 '26	Sale	261.41	18,950	4,953,694	78,691	Feb 23 07:14 PM
ROSSI DINO A	Director	Feb 19 '26	Proposed Sale	261.41	18,950	4,953,694		Feb 19 12:09 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 09 '26	Option Exercise	63.55	12,500	794,375	31,818	Feb 11 07:08 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 09 '26	Sale	272.14	12,500	3,401,705	19,318	Feb 11 07:08 PM
ROMANO KATHRYN	Officer	Feb 09 '26	Proposed Sale	276.66	12,500	3,458,250		Feb 09 04:04 PM
Krishnan Suma	President, R&D	Dec 04 '25	Sale	220.16	25,000	5,503,938	1,413,711	Dec 05 06:56 PM
Krishnan Suma	President, R&D	Dec 04 '25	Sale	220.14	25,000	5,503,395	1,483,056	Dec 05 06:56 PM
Krishnan Krish S	President and CEO	Dec 04 '25	Sale	220.16	25,000	5,503,938	1,413,711	Dec 05 06:53 PM
Krishnan Krish S	President and CEO	Dec 04 '25	Sale	220.14	25,000	5,503,509	1,483,056	Dec 05 06:53 PM
KRISH KRISHNAN	Director	Dec 04 '25	Proposed Sale	217.46	25,000	5,436,500		Dec 04 04:40 PM
SUMA KRISHNAN	Director	Dec 04 '25	Proposed Sale	217.46	25,000	5,436,500		Dec 04 04:38 PM

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

M.S.Mr. Krish S. Krishnan M.B.A.

FounderMs. Suma M. Krishnan

Executive VP & Chief Accounting OfficerMs. Kathryn A. Romano CPA

EVPMr. John C. Thomas

Vice President of North American Sales & MarketingMr. John Karakkal

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KRYS

Krystal Biotech Inc

Upgrade your Finviz experience